Table 4. Changes of baseline HF and baseline BCVA after anti-VEGF treatment.

Main outcomes	CRVO						BRVO
	Ischemic			Non-ischemic
	Baseline	Final	P	Baseline	Final	P	Baseline	Final	P
BCVA	49.36±18.11	55.93±20.47	0.361	57.67±7.98	69.33±14.70	0.002	60.13±9.68	76.67±6.34	0.0001
CRT	841.14±266.21	308.79±147.09	0	659.57±136.19	302.43±122.16	0.0000	549.07±125.11	292.8±72.96	0.0001
HF in retinal layer	83.36±115.80	42.29±64.94	0.272	54.76±73.64	19.76±26.83	0.020	61.67±98.11	17.33±22.52	0.106
HF in ORL	10.86±24.56	6.57±15.52	0.611	4.05 ± 6.17	0.57 ± 1.25	0.015	4.80 ± 5.58	2.13 ± 2.78	0.027
HF in IRL	72.50±109.35	36.43±59.67	0.290	50.76±70.54	18.71±26.89	0.024	56.93±95.80	15.27±21.40	0.126
RATIO	0.225±0.221	0.112±0.129	0.105	0.471±0.615	0.051±0.041	0.005	0.248±0.064	0.089±0.023	0.035